Introduction Although excellent results have been reported with the use of allogeneic or autologous transplantation for patients with acute myeloid leukemia (AML) in first complete remission (CR), most patients are not transplanted while in first CR. There are a number of reasons for this. Some patients never achieve a first remission. Other patients achieve a first remission and are transplant candidates, but a deliberate decision is made by the physician and/or patient to pursue further chemotherapy and reserve transplantation until relapse. Finally, there are patients who achieve a first remission but, because of age or comorbidities, are not felt to be transplant candidates. In this brief review, all three categories of patients will be considered.
Transplantation for primary induction failure Several studies have shown that long-term survival is possible when allogeneic transplantation is used to treat patients who have failed initial induction chemotherapy. For example, in the experience of the European Bone Marrow Transplant Group, long-term survival was achieved with matched sibling transplantation in 20% of such patients. 1 These results emphasize the importance of HLA-typing patients and family members at diagnosis, so that valuable time will not be lost in identifying a suitable source of allogeneic stem cells should remission attempts fail. These results also raise the question of whether we sometimes persist too long in attempting to achieve a complete remission. Is a second cycle of induction worth it for a patient with a matched sibling who has achieved a good partial response with the initial cycle of induction?
Transplantation as salvage therapy for patients with matched siblings Patients less than age 56 years with matched siblings who relapse after an initial remission in almost all cases should be considered transplant candidates. There are occasional relapsed patients with first remissions of long duration and favorable cytogenetics who may do reasonably well with further chemotherapy, but such individuals are uncommon and transplantation is most often the treatment of choice. 2 Whether patients with AML in first relapse should be reinduced prior to transplantation is an interesting question. Studies have shown a 25-30% cure rate for patients transplanted in first relapse without reinduction. For example, our center reported a 28% 5-year disease-free survival among 126 patients transplanted for AML in first untreated relapse. 3 rates with matched sibling transplantation for AML in second remission are not markedly higher than this. For example, the European registry reported a 35% 3-year disease-free survival rate among 459 patients transplanted from matched siblings for AML in second remission. 4 Further, only approximately 50% of patients in first relapse will be successfully reinduced and 15-20% may die during attempted reinduction. While no prospective study has addressed this question, our general philosophy in Seattle is to proceed directly to transplant if relapse is diagnosed before patients have substantial numbers of circulating blasts and if the transplant can be initiated promptly. If, however, patients have circulating blasts or a substantial amount of time is required to organize the logistics of the transplant, then reinduction is generally recommended.
There have been no randomized trials addressing the best preparative regimen, source of stem cells, or form of graftversus-host disease prophylaxis specifically focused on patients with AML in second remission undergoing transplantation from matched siblings. The International Bone Marrow Transplant Registry reported on 257 patients transplanted prior to 1990 and found a 26% 3-year disease-free survival, with better results seen in patients less than age 31 years and with first remissions lasting longer than 1 year. 2 Transplantation as salvage therapy for patients without matched siblings Patients with AML is second remission, but without matched siblings, are potential candidates for either autologous or unrelated hematopoietic cell transplantation. There have been no randomized trials comparing either approach to further chemotherapy or the two approaches to each other. Results for autologous transplantation in second remission have reported 3-year leukemia-free survival rates ranging anywhere from 21 to 52% with registry data settling at about a 30% disease-free survival rate. 5 Factors affecting outcome include age and duration of first remission. A retrospective matched-pair analysis was conducted comparing the outcome in 340 patients with AML in second remission transplanted using either autologous or matched sibling marrow. 6 While treatment-related mortality was higher after allogeneic transplantation, relapse rates were lower and overall survival somewhat better with the allogeneic approach (39% vs 30%) at 4 years. There are fewer data available reporting on the use of matched unrelated donor transplants for AML in second remission. Our recent experience in Seattle shows a 28% disease-free survival rate among 40 patients. 7 This result is similar to the 31% 5-year survival rate reported by the National Marrow Donor Program among 473 patients. 8 In Seattle, better results were seen among younger patients and those transplanted with increased numbers of CD34 + cells in the stem cell inoculum.
While the results attained to date suggest that both autologous and matched unrelated donor transplantation offer an advantage over continued chemotherapy for most patients with AML in second remission, there are very few data comparing the two approaches to each other. A case controlled study was conducted by the European Bone Marrow Transplant Group in which the outcome of 46 unrelated donor transplants for AML in second remission was compared with twice that many autologous transplants matched for major risk factors. 9 No statistically significant difference in outcome was seen. Without further data to rely on, matched unrelated transplants might be chosen for younger patients with leukemias associated with poor risk factors (short first remission, unfavorable cytogenetics), while autologous transplantation might be considered for older patients with disease characterized by more favorable prognostic factors.
Transplantation as an option for older patients, or those with comorbidities Because the outcome of allogeneic transplantation is worse in older patients, many physicians have been reluctant to attempt this approach in individuals over age 55 years. The existence of a powerful graft-versus-tumor effect, as evidenced by the association of graft-versus-host disease with decreased relapsed rates and the complete responses seen following donor lymphocyte infusions, has encouraged studies of less intense preparative regimens as a means of obtaining full donor chimerism with acceptable toxicity. As one example, investigators at the Fred Hutchinson Cancer Research Center have shown that full donor chimerism can be obtained in virtually all matched siblings using a nonmyeloablative regimen of fludarabine 30 mg/m 2 for 3 days and 200 cGy total body irradiation. 10 The 100-day mortality with this approach has generally been less than 5%, even though the median age of patients treated to date has been 60. Among six patients with AML in second remission, aged 60-71, three are alive and well in complete remission now more than 1 year from transplant. Similar approaches are being studied by a number of other investigators.
Inducing patients into second remission For those patients not transplanted in untreated first relapse, physicians are faced with the difficult task of choosing appropriate regimens for reinduction. A number of large observational reports, each totaling more than 100 patients, have been published over the last 15 years. [11] [12] [13] [14] [15] In general, complete response rates have ranged from 30 to 50% and the mortality associated with reinduction has been between 15 and 25%. In these studies, three prognostic factors have consistently been identified: the age of the patient, the cytogenetic risk group of the leukemia, and the duration of first remission.
There have been a limited number of large randomized studies that have focused on relapsed AML. Vogler 16 looked at the question of whether the addition of VP-16 added to the effectiveness of high-dose cytarabine. The complete response rates were 40% with high-dose cytarabine and 45% with the addition of the VP-16, not a significant difference. Kern et al ) on days 1, 2, 7 and 8 vs higher-dose cytarabine (3 g/m 2 on the same schedule) when both were combined with mitoxantrone and found complete response rates of approximately 47% for both approaches. Karanas et al 18 found that when results seen with high-dose ara-C alone were compared to high-dose ara-C plus mitoxantrone, a significantly higher response rate was seen with the addition of mitoxantrone, but that this did not translate into improved overall survival. Finally, List et al 19 have shown in a prospective randomized study that the addition of cyclosporine to a combination of high-dose ara-C and daunomycin in an effort to reverse the impact of multidrug resistance did reduce the incidence of resistant disease and led to improved diseasefree and overall survival.
An obvious problem with all of these aggressive reinduction regimens is that while patients may achieve a second complete remission, they may also suffer significant organ damage or may acquire stubborn persistent infections, which may significantly diminish the likelihood of a successful subsequent transplant. Thus, the search for effective less toxic reinduction combinations continues.
